Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 5901–5950 of 18416
Manuel C. Alves-Aivado, M.D., Ph.D., agreed that his employment with the Company would cease and he would resign from his position as Chief Executive Officer of the Company, effective as of March 11, 2024
On March 14, 2024, Frank Karbe resigned from his position as CEO, President, Treasurer and Secretary.
On March 14, 2024, the Board appointed Craig R. Jalbert, age 61, as the Company’s CEO, President, Treasurer, Secretary, and sole member of the Board.
John Butler, the Company’s President and Chief Executive Officer, will act as interim principal financial officer from the Transition Date.
On March 15, 2024, Akebia Therapeutics, Inc. (the “Company”) and Ellen Snow mutually agreed that she would transition from her role as the Company’s Senior Vice President, Chief Financial Officer and Treasurer, effective March 22, 2024 (the “Transition Date”).
the following individuals were appointed to serve as executive officers of the Company: Name Position Tie (James) Li Chief Executive Officer Zhiyi (Jonathan) Zhang President George Yutuc Chief Financial Officer Darin Carpenter Chief Operating Officer Varto Doudakian Vice President
the following individuals were appointed to serve as executive officers of the Company: Name Position Tie (James) Li Chief Executive Officer Zhiyi (Jonathan) Zhang President George Yutuc Chief Financial Officer Darin Carpenter Chief Operating Officer Varto Doudakian Vice President
Mr. Nadir Ali and Ms. Wendy Loundermon resigned as Chief Executive Officer and Chief Financial Officer of the Company, respectively.
the board of directors of the Company (the "Board") appointed Mr. Scott Pomeroy as Chief Executive Officer of the Company and Ms. Brooke Martellaro as Chief Financial Officer of the Company.
Mr. Nadir Ali and Ms. Wendy Loundermon resigned as Chief Executive Officer and Chief Financial Officer of the Company, respectively.
the board of directors of the Company (the "Board") appointed Mr. Scott Pomeroy as Chief Executive Officer of the Company and Ms. Brooke Martellaro as Chief Financial Officer of the Company.
Effective March 14, 2024, Nelson Cabatuan, age 46, has been appointed to the position of Chief Financial Officer of Lexaria Bioscience Corp.
On March 13, 2024, Meng-Lin Sung, the Chief Financial Officer of Ainos, Inc. (the “Company”), resigned from her positions with the Company, effective as of such date.
As of the Effective Date, Joseph Jordan, the Company’s Chief Financial Officer, will serve as the Company’s principal financial officer and principal accounting officer.
the Board announced the appointment of Mr. Sanjay Chowbey to serve as Kennametal’s President and Chief Executive Officer starting on June 1, 2024.
On the Effective Date, the Debtors’ officers, including Mr. Gareth T. Joyce, Chief Executive Officer and President of the Company, and Mr. Justin Derek Pugh, Acting Chief Financial Officer of the Company, were replaced pursuant to the Plan by the Reorganized Debtors’ new officers, each effective as of March 13, 2024.
On the Effective Date, the Debtors’ officers, including Mr. Gareth T. Joyce, Chief Executive Officer and President of the Company, and Mr. Justin Derek Pugh, Acting Chief Financial Officer of the Company, were replaced pursuant to the Plan by the Reorganized Debtors’ new officers, each effective as of March 13, 2024.
the Company appointed Adam Miller as the Company’s Chief Executive Officer and Andrew Hess as the Company’s Chief Financial Officer, both effective February 26, 2024.
the Company appointed Adam Miller as the Company’s Chief Executive Officer and Andrew Hess as the Company’s Chief Financial Officer, both effective February 26, 2024.
David A. Jackson stepped down as Chief Executive Officer of the Company and as a member of the Board.
the Company announced the promotion of Landen Fredrick to President and Chief Executive Officer (“CEO”) effective April 1, 2024
announcing the retirement of Alfredo (Al) Bala as the Company’s Chief Executive Officer effective April 1, 2024
the Board approved the appointment of Jonathan Cherry to serve as President and Chief Executive Officer of the Company and as a member of the Board, effective March 14, 2024.
On March 13, 2024, Laurel Sayer tendered her notice of resignation to the board of directors (the “ Board ”) of Perpetua Resources Corp. (the “ Company ”), notifying the Company of her resignation as President and Chief Executive Officer of the Company and as a member of the Board, effective March 14, 2024
On March 8, 2024, Bo Kruse, Executive Vice President, Chief Financial Officer, Secretary and Treasurer of Y-mAbs Therapeutics, Inc. (the “Company”), informed the Company of his intention to resign from such offices effective as of the date the Company appoints his successor and such successor commences employment with the Company (the “Successor Effective Date”) and to resign from employment with the Company effective July 31, 2024 (the “Effective Date”).
Joseph Otting will assume the role of President and Chief Executive Officer of the Company as of April 1, 2024.
appointed David Rosal, age 61, as its Chief Financial Officer, effective immediately.
On March 8, 2024, Timothy G. Hannon, Chief Financial Officer and principal accounting officer of WaveDancer, Inc. (the “Company”) resigned from the Company effective March 22, 2024, in order to accept another career opportunity.
On March 8, 2024, PetVivo Holdings, Inc. (the “Company”) appointed Garry Lowenthal to serve as the Company’s Chief Financial Officer.
the Board has appointed Sami Siddiqui to succeed Matthew Dunnigan as Chief Financial Officer of the Company
the Board has appointed Sami Siddiqui to succeed Matthew Dunnigan as Chief Financial Officer of the Company
The final terms of Mr. Dunnigan’s separation from the Company and termination of his employment are in the process of being finalized as of the date of this current report on Form 8-K.
the Board has appointed Sami Siddiqui to succeed Matthew Dunnigan as Chief Financial Officer of the Company
On March 12, 2024, the Board of Directors (the “Board of Directors”) of Comtech Telecommunications Corp. (“Comtech” or the “Company”) terminated Ken Peterman as President and Chief Executive Officer of the Company for cause due to conduct unrelated to Comtech’s business strategy, financial results or previously filed financial statements.
John Ratigan, age 63, who is currently the Company’s Chief Corporate Development Officer (“CCDO”), will serve as interim Chief Executive Officer, effective immediately.
On March 12, 2024, Stephen L. Faulkner, Jr. (Larry) informed Empire Petroleum Corporation (the “Company”) that he was resigning as Chief Financial Officer and Chief Accounting Officer of the Company effective on or about March 28, 2024.
On March 8, 2024, the Company accepted the resignation of Mr. Chris Wang as Chief Financial Officer of the Company effective as of March 8, 2024.
On March 12, 2024, the Board of Directors of Phoenix Motor Inc. (the “Company”) appointed Mr. J. Mark Hastings as the Company’s Chief Financial Officer, effective immediately.
Mr. Bailey has been in a transitional role and his employment formally ended effective March 12, 2024.
the Board has appointed Jeffrey N. Boyer as interim Chief Executive Officer
Kosta N. Kartsotis is stepping down from his position as Chief Executive Officer and a member of the Board of Directors
Ronald V. Coughlin, Jr., whose role as the Company’s Chief Executive Officer, Chairman and member of the Board ended effective March 12, 2024.
Edward J. Wegel was terminated as the Company’s Chief Executive Officer and Chairman of the Board of Directors, effective of February 5, 2024.
Jamie Martin has been appointed to serve as Senior Vice President and Chief Financial Officer
On March 11, 2024, the Board received and accepted the resignation of Jason T. Roos from his position as the Chief Financial Officer of the Company, effective March 31, 2024.
On March 11, 2024, Brandon Satoren was appointed by the board of directors (the “Board”) of Logan Ridge Finance Corporation (the “Company”) as the new Chief Financial Officer of the Company, effective April 1, 2024.
Effective April 1, 2024, the Board appointed Kevin A. Plank, the Company’s current Executive Chair and Brand Chief, to serve as the Company’s President and Chief Executive Officer (and principal executive officer).
Effective March 31, 2024, Brian Riley, Senior Vice President of Finance, will become GBLI’s Chief Financial Officer.
Thomas M. McGeehan, Chief Financial Officer, will retire effective March 31, 2024.
On March 12, 2024, the Company appointed Warren Wang as its Chief Executive Officer and Chairman of the Board.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.